State of the Funding in 2015

In 2015, preliminary reported funding for HIV prevention R&D decreased from US$ 1.25 billion in 2014 to US$1.18 billion. However, overall funding has remained essentially flat for over a decade. While investments towards research for preventive vaccines and female condoms increased from 2014 levels, investments towards microbicides, PrEP, TasP, VMMC, declined. Prevention of vertical transmission remained almost flat-funded in 2015.

The US public sector remained the single largest source of funding for HIV prevention R&D, with a total investment of US$836 million. European public sector investment continued its decade-long decline, falling US$8 million from 2014. Public sector funding outside the US and Europe also continued to fall, decreasing another US$5 million in 2015 for a total US$18 million decline since 2013. Finally, the philanthropic sector comprised 13% of all funding at US$155 million, a 23 percent decrease from 2014 contributions, while the commercial sector increased its contribution to HIV prevention R&D by 19 percent over 2014.